Viromed Medical AG, a medical technology company specializing in cold plasma technology, published its half-year report for 2026, highlighting advancements in product development, regulatory approvals, and strategic partnerships. The company also confirmed its full-year guidance, expecting a significant increase in consolidated revenue and net income. The report, released via NEWMEDIAWIRE, underscores Viromed's progress in bringing its innovative cold plasma products to market.
During the first half of 2026, Viromed continued preclinical development of PulmoPlas®, initiated OEM production of ViroCAP® for HELLMUT RUCK GmbH, and secured an exclusive sales partnership with NEBU-TEC for veterinary applications of PulmoPlas®. Notably, the company completed the conformity assessment procedure for ViroCAP® med as a Class IIa medical device under the EU Medical Device Regulation (MDR), receiving official approval in early July 2026. This certification allows Viromed to begin sales of ViroCAP® med, a key milestone for the company. Additionally, Viromed was granted a research allowance of EUR 550,000 for research and development projects in cold plasma technology.
Financially, Viromed reported consolidated revenue of EUR 2.5 million in H1 2026, a slight increase from EUR 2.4 million in the same period of 2025. The net loss for the period was EUR 1.1 million, compared to EUR 0.8 million in H1 2025, attributed to expenses related to the PulmoPlas® study and the approval and market launch of ViroCAP® med. Despite the loss, the company's equity increased by 43.9% to EUR 9.5 million as of June 30, 2026, with an equity ratio of 67.6%, up from 39.9% a year earlier. This improvement reflects a stronger balance sheet and enhanced financial stability.
CEO Uwe Perbandt commented, “We successfully continued developing our products in the first half of the year while also making important progress in preclinical research. The planned publication of the study results in a renowned scientific journal will further strengthen the scientific evidence supporting our cold plasma technology. This will give us greater visibility and a solid foundation for the next steps in the further development and marketing of our products.” The publication of study results is expected to bolster the company's credibility and support future growth.
The company financed itself primarily through a EUR 2.7 million loan from Perbamed Invest GmbH during the reporting period, which was reviewed and approved by the supervisory board and tax advisor. Looking ahead, Viromed confirms its full-year guidance, as adjusted on May 8, 2026, anticipating a significant increase in revenue and net income for the 2026 financial year. The half-year financial statements are available on the Viromed Medical AG website.
This news is significant for the medical technology industry and investors, as Viromed's advancements in cold plasma technology could lead to new treatment options and drive growth in the healthcare sector. The successful regulatory approval and strategic partnerships position the company to capitalize on the expanding market for innovative medical devices. For readers, this development highlights the potential of cold plasma technology to address unmet medical needs, while the company's financial progress and confirmed guidance signal confidence in its long-term strategy.
